Soluble Endoglin Level Increase Occurs Prior to Development of Subclinical Structural Vascular Alterations in Diabetic Adolescents.


Creative Commons License

Emeksiz H. C., BİDECİ A., Damar C., Derinkuyu B. E., Celik N., DÖĞER E., ...More

Journal of clinical research in pediatric endocrinology, vol.8, no.3, pp.313-20, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.4274/jcrpe.2906
  • Journal Name: Journal of clinical research in pediatric endocrinology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.313-20
  • Keywords: Type 1 diabetes mellitus, subclinical atherosclerosis, soluble endoglin, adolescents, FLOW-MEDIATED DILATION, TGF-BETA RECEPTOR, NITRIC-OXIDE, ASYMMETRIC DIMETHYLARGININE, ENDOTHELIAL DYSFUNCTION, CHILDREN, ATHEROSCLEROSIS, EXPRESSION, MELLITUS, CELLS
  • Gazi University Affiliated: Yes

Abstract

Objective: Soluble endoglin (S-endoglin) has been implicated as a potential marker of endothelial dysfunction (ED) and was reported to be elevated in diabetic adults, correlating with the severity of diabetic vasculopathy. However, circulating S-endoglin and its association with other markers of ED have not been formerly analyzed in the first decade of diabetes onset in adolescents with type 1 diabetes mellitus (T1DM).